Zura Bio Limited Class A Ordinary Shares (ZURA) is a Healthcare · Biotechnology company listed on NASDAQ. Price $4.46 (-2.41%), Market cap $0.45B, 52-week low–high $1.00 ~ $7.04.
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development. It also develops Torudokimab (ZB-880), a fully human immunoglobulin G4 monoclonal antibody targeting interleukin-33 that has completed Phase 1 clinical studies; and Crebankitug (ZB-168), a fully human immunoglobulin G1 monoclonal antibody targeting interleukin-7 receptor alpha that has completed Phase 1 clinical st
Financial statements, price targets, institutional (13F) holdings and related news for Zura Bio Limited Class A Ordinary Shares are updated in real time on BlackAll Trade.
Zura Bio Limited Class A Ordinary Shares trades at $4.46 (-2.41%). Real-time quotes and charts are available on BlackAll Trade.
Zura Bio Limited Class A Ordinary Shares has a market cap of about $0.45B.
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-c